Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Solomon To Step Aside As Forest Exec; Icahn Wins Another Victory

This article was originally published in The Pink Sheet Daily

Executive Summary

President and CEO of Forest Laboratories Howard Solomon will retire at the end of the year. Activist investor Carl Icahn has long inveighed against the 85 year-old exec. This could signal a renewed effort to get Forest back on track, now that its Lexapro losses have slashed revenue and a Namenda expiry looms.

You may also be interested in...



Forest’s New CEO Talks Change, But Offers Few Specifics

Forest’s new CEO laid out the broad parameters of potential change at the company, although specifics await a January investor meeting. In his first earnings call since taking control, Brent Saunders emphasized the near-term priorities of cost-control, recent and upcoming launch execution, and lifecycle management.

Forest’s Board Grows, As Icahn Gains Second Director’s Seat

Dissident shareholder Carl Icahn will have some influence on the succession process as the New York drugmaker seeks a replacement for its retiring octogenarian CEO. Forest still needs to compensate for the loss of blockbuster antidepressant Lexapro, and could consider a sale or dramatic restructuring.

Many New Products For Forest, But Not Enough To Fill The Lexapro Gap

The launches of Tudorza for COPD and Linzess for irritable bowel syndrome are off to strong starts, Forest executives said during the company’s fiscal fourth quarter sales and earnings call. But despite those and other recent entries, the company reported a net loss for the year after revenues nose-dived from the loss of Lexapro.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075734

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel